C
프레스티지바이오로직스
334970KOSDAQ54.3 / 100
Reference Date: 2026-09-08
Financial Score19.0 / 40
News Sentiment21.3 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 13.3% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
Prestige BioLogics specializes in contract manufacturing of advanced biopharmaceuticals for domestic and international pharmaceutical companies, offering customized services throughout the development process via its CDEMO business model. In the first half of 2024, antibody drug sales accounted for 68% of total revenue.
Number of Employees
279people
Average Salary
42.2M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
0.99Industry Average 1.204.0Point
In line with industry avg
ROE
-26.56Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
24.16Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20253.0 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲251.6% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼26.0% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -30.4% (improving, 2yr)
Detailed News Sentiment
1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85
- Positive프레스티지바이오로직스, 역대 최대 분기 실적 달성
프레스티지바이오로직스가 역대 최대 분기 매출 달성으로 긍정적인 실적을 발표했다.
Detailed Momentum
52-week position1.0Point
Near 52w low (0%, downtrend)
Current 1,722Won52-week high 3,77052-week low 1,721
1-month return1.0Point
1m -13.29% (falling)
Volume trend2.0Point
Volume decreasing
Detailed Disclosure
1 totalPositive 0Neutral 1Negative 0
- Neutral매출액또는손익구조30%(대규모법인은15%)이상변동2026-08-14